THYROID CANCERS

Lung Cancer

Lung Cancer

Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with&nbsp;relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission.&nbsp;<br /> &nbsp;

Lori J. Wirth, MD, discusses the era of precision genotype targeted therapy in advanced thyroid cancer, with a focus on individual targets in subtypes of thyroid cancer.&nbsp;

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.

A study presented at the 2017 Cancer Survivorship Symposium revealed a long-term cardiovascular risk associated with administration of levothyroxine.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Jochen H. Lorch, MD, MS&nbsp;discusses&nbsp;current approved treatment options for patients with MTC, the biology of the disease, managing potential progression, and future possibilities in the treatment of MTC.

With anaplastic thyroid cancer (ATC) being a rare disease that often has poor prognoses, researchers are seeking therapies for these patients that are more promising than surgery or radiation.

William Cance, MD, has recently joined the University of Arizona Cancer Center (UACC) as Deputy Director.